Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have ... and sustained weight loss," Wegovy is "the ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

They found Zepound users lost nearly 50% more weight than Wegovy users. The study, which was funded by Zepbound ... loss drugs raises questions about access, cost, and overall health care strategies ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...